Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases. by Webster, Ruth et al.
Webster R, et al. Implementing Fixed Dose Combination Medications 
for the Prevention and Control of Cardiovascular Diseases. Global 
Heart. 2020; 15(1): 57. DOI: https://doi.org/10.5334/gh.860
EDITORIAL VIEWPOINT
Implementing Fixed Dose Combination Medications 
for the Prevention and Control of Cardiovascular 
Diseases
Ruth Webster1,2, Adrianna Murphy3, Helen Bygrave4, Éimhín Ansbro3, Diederick 
E. Grobbee5 and Pablo Perel3,6
1 Centre for Health Economics Research and Evaluation, University of Technology Sydney, AU
2 The George Institute for Global Health, The University of New South Wales, Sydney, AU
3 Centre for Global Chronic Diseases, London School of Hygiene and Tropical Medicine, London, UK
4 Médecins Sans Frontières Access Campaign, Geneva, CH
5 UMC Utrecht, Utrecht, NL
6 World Heart Federation, Geneva, CH
Corresponding author: Ruth Webster (Ruth.Webster@chere.uts.edu.au)
Highlights:
-  Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular 
disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.
-  A symposium was held bringing together stakeholders on this issue, including from academia, 
government and NGOs.
-  The conclusion made was that what is now needed to improve implementation of FDCs is 
country-specific health systems analyses to design appropriate implementation strategies.
-  Implementation strategies must look beyond listing on the WHO Essential Medicines List to 
consider approaches to improving FDC availability, accessibility, affordability, and adherence.
-  Strategies might include incorporation of FDCs into the WHO HEARTS technical package, 
simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and 
task-sharing for treatment management.
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The Problem
The political declaration on non-communicable diseases (NCD) adopted by the UN general assembly in 
2011 acknowledged the growing epidemic of NCDs that is occurring primarily in low and middle-income 
countries (LMIC). In response to this, the World Health Organization (WHO) global action plan (25 × 25 
goals) outlined nine global voluntary targets to reduce premature death from the four major NCDs by 25% 
by 2025 [1]. Included in these is the target to have at least 50% of eligible people (defined as age 40 years 
or older with a 10-year calculated cardiovascular risk of at least 30% or established cardiovascular disease) 
receiving drug therapy and counseling to prevent heart attack and stroke by 2025. An associated target is 
to achieve 80% availability of affordable, safe, and efficacious essential medicines for the management of 
NCDs, including cardiovascular disease. The more recent Sustainable Development Goals are aligned with 
the WHO 25 × 25 plan and aim to reduce premature NCDs by one third by 2030.
There is high-quality evidence of efficacious and safe medicines to reduce the risk of further cardiovas-
cular events for people with established CVD (including statin, blood pressure-lowering drugs, and aspirin) 
and those diagnosed with hypertension. However, these medicines are currently largely not taken by the 
majority of high-risk patients globally. The reasons for this are complex, including interwoven factors at the 
health system level, prescriber, and patient levels. These include poor availability of drugs, lack of afford-
ability and/or access for the patient, lack of affordability to the health system, the complexity of multi-pill 
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regimens for the patient, number of pills required to be prescribed (associated with physician inertia) and 
poor adherence by the patient. In the context of CVD preventive medications, the PURE study, a large cross-
sectional study conducted in 18 countries, showed that the majority of communities in LMIC had less than 
60% availability of recommended CVD preventive medications and that availability could be as low as 3% 
[2]. Affordability of these medications was also shown to be limited, with the proportion of households at 
risk of being unable to afford essential drugs ranging from 20% in the highest income earners to 88% in the 
lowest income earners. Unsurprisingly, proportions of people with established CVD in these communities 
who take all recommended CVD preventive medications are extremely low [3]. Even in high-income settings, 
where availability and affordability are generally less of a problem than in low-income settings, adherence 
rates (proportion of patients who take their medications as prescribed) are consistently low and average 
around 50% [4] or even lower [5, 6]. Innovative strategies involving improved medication availability, afford-
ability, access, and prescribing and adherence support to improve the use of CVD preventive medications 
globally are required if the 25 × 25 target is to be achieved. The commonality of risk factors responsible for 
CVD between high-income countries and low-income countries ensures that any solutions found, may have 
the potential (within the bounds of adaptation to the local context) to provide benefits for a broad range of 
countries across the economic spectrum.
Precedent for Using Fixed Dose Combinations (FDCs) to Transform Access 
to Care
There are well-established precedents for the wide use of fixed-dose combination medications (FDCs) for 
chronic illnesses. For example, FDCs are recommended as first-line treatment in clinical guidelines for tuber-
culosis [7] and HIV [8]. With HIV specifically, development of a one pill, once a day, minimal toxicity regimen 
that could be applied across subpopulations, has allowed decentralization of treatment and task-sharing 
by simplifying prescribing and monitoring requirements [9]. Available research on this approach to HIV 
treatment has shown improved adherence to therapy [10], as well as patient and provider preference over 
multi-pill regimes [11]. The potential for operational benefits of FDCs has also been noted by experts con-
vened by WHO at a roundtable in 2003 who reported increased security of supply systems and lower drug 
supply costs, associated with improved production, storage, transport, dispensing and other health system 
components [9]. Treatment guidelines incorporating these simplified regimens have thus moved away from 
an individualised approach and taken a public health approach, identifying the best option for the majority 
and ensuring that they have continued access whilst recognising that alternatives are needed for the minor-
ity that may have medical contraindications and/or side effects. Availability of FDCs and this public health 
approach to guidelines are acknowledged as key components in the successful strategy to scale-up HIV treat-
ment globally [9]. The benefits of FDCs for CVD prevention and control are likely to be similar.
Evidence for FDCs in CVD Prevention and Control
The combination of multiple classes of low-cost generic CVD preventive medications into one pill was ini-
tially proposed by WHO in 2001 [12]. It was noted in this report that FDC medications had the capacity to 
overcome poor adherence to treatment (due to a multiplicity of pills); inadequate dosage (due to variability 
in prescribing practices of physicians); and cost and availability barriers of drugs. FDCs, therefore, have the 
capacity to address multiple points in the chain of potential barriers to adequate CVD preventive and treat-
ment medication coverage.
FDC for secondary prevention
Several randomized, placebo-controlled trials have now confirmed that FDCs improve blood pressure and 
cholesterol compared to usual care [13], and to the same degree and with similar rates of adverse events 
compared to individual component drugs [14–17]. Most recently, the first FDC trial to look at CVD outcomes 
(PolyIran) found a reduction in major CVD events among the polypill group compared to minimal care 
(adjusted hazard ratio (HR) 0.66, 95% CI 0.55–0.80) and this reduction was more pronounced when analys-
ing those with the highest adherence alone (adjusted HR 0.43, 95% CI 0.33–0.55) [18]. 
Four trials (UMPIRE, IMPACT, Kanyini-GAP, and FOCUS) have assessed the effects of FDCs in patients either 
with an established disease or at high calculated risk (≥15% over five years) on adherence, LDL choles-
terol, and systolic blood pressure compared to either usual care or separate drug components [19–22]. All 
four trials have shown improvements in adherence to CVD preventive medication with the use of a polyp-
ill with absolute increases ranging from 25% to 40% at 12 months. A meta-analysis of the Single Pill to 
Avert Cardiovascular Event (SPACE) Collaboration group of 3 trials (UMPIRE, IMPACT, and Kanyini-GAP) also 
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showed an improvement in SBP (–2.46 mmHg, 95%CI: –4.55 to –0.37) and LDL-C (–0.09 mmol/L, 95%CI: 
–0.18 to 0.00) [23]. 
In the SPACE Collaboration trials, the trial design did not require stabilisation of patients on polypill com-
ponent drugs at specific doses prior to randomisation. In fact, the largest benefits (RR 4.46, 95% CI 3.72 to 
5.36) were seen in patients who were not receiving all recommended treatment at baseline. No safety issues 
were identified with this approach, thereby supporting the use of FDC therapy not only as a substitution 
therapy for patients already stabilised on existing medications but also as ‘step-up’ therapy to immediately 
move patients from being on no treatment or partial treatment to full treatment.
Analysis of reported safety data in trials to date shows no safety concerns as yet. However, broader post-
marketing surveillance is recommended [24].
FDCs for hypertension
The evidence for benefit in FDCs for the treatment of hypertension is well established, showing clear 
improvements in adherence [25] as well as the reduction in cardiovascular events for patients using com-
bination therapy vs. individual tablets [26]. Additionally, the recent TRIUMPH study [27] a randomised con-
trolled trial of low dose triple combination therapy vs. usual care demonstrated a significant improvement 
in the proportion of patients reaching their blood pressure targets within six weeks when a low dose triple 
combination pill was prescribed for patients either not on therapy or uncontrolled on monotherapy, thus 
supporting the early use of low dose combination therapy within a simplified treatment regimen to improve 
early blood pressure control. Guidelines such as the 2017 American Heart Association Hypertension guide-
lines [28] already endorse the use of FDCs in hypertension to improve adherence, with the initiation of treat-
ment with multiple drugs recommended in patients with blood pressure > 20/10 mmHg above their target. 
The 2018 European Society of Hypertension guidelines have also moved to broaden their recommendations 
to acknowledge that combination therapy is now recognized as the most effective initial treatment strategy 
in most patients, with no specific threshold for initiation of combination therapy [29].
Potential Global Impact of FDCs for CVD
Making an affordable FDC available in low- and middle-income countries has, therefore, the potential to 
contribute significantly to the global WHO CVD goals in a cost-effective manner and will assist in meeting 
the goal for coverage of preventive medications in at least 50% of the population [1, 30]. Additionally, use 
of FDCs is fully compatible with established WHO strategies for CVD prevention as multidrug therapy is 
already recognised as a ‘best-buy’ by WHO [31], and recommendations for the use of FDCs is included in 
WHO recommendations including the WHO HEARTS technical package for management of cardiovascular 
disease which includes two suggested regimens for blood pressure control incorporating use of combina-
tion therapy [32].
Scaling up FDCs for CVD
Successful scale-up of FDCs in low- and middle-income countries will require listing on the WHO Essential 
Medicines List (EML) as WHO endorsement is viewed as highly important, if not essential, by partner coun-
tries for any proposed scale-up or implementation of specific drug therapy. 
Three applications (with increasing amounts of evidence) have been made to the EML since 2013 for 
the inclusion of CVD polypills onto the list, with all three applications being rejected. Several reasons for 
rejection have been reported by the WHO EML expert committees, including the perceived complexity of 
management of hypertension and cardiovascular disease, the need to individualise dose through titration 
of medications, and the challenge to prioritise which of the multiple available FDCs should be included. 
The differences with FDC use for infectious diseases (which are indeed included in the WHO EML and have 
been successfully scaled up) have also been stated. The need for FDCs to avoid microbial resistance is, of 
course, recognised as a feature exclusive to infectious disease. However, the benefits noted above, both for 
the health system and for patient adherence, should provide valuable programmatic experience to support 
their use in scale-up activities.
Progress has been seen, however, with the successful listing of four different combinations of FDCs for 
hypertension on the WHO EML in 2019 (Lisinopril/amlodipine, Lisinopril/hydrochlorothiazide, telmisar-
tan/amlodipine, telmisartan/hydrochlorothiazide).
To address these challenges with obtaining EML approval for FDCs, and with the objective to bring 
together different perspectives and stakeholder views about this matter, a symposium was organized on July 
3rd by the London School of Hygiene & Tropical Medicine, Centre for Global Chronic Conditions, The George 
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Institute for Global Health, and Médecins Sans Frontières. The symposium brought together cardiovascular 
and infectious disease research communities, governments, WHO, funders, private sector, and civil society, 
among others. 
One of the main conclusions of this symposium was that simply making CVD FDCs (both polypills and 
FDCs for hypertension) available on the WHO EML and in the market is unlikely to have a large effect by 
itself. In order for CVD FDCs to be scaled up, they should be included as part of a larger strategy (as has been 
done for HIV, for example) for improving availability, accessibility, affordability, and adherence to medicines, 
and the design of appropriate health system delivery models [33]. Among other components, this strategy 
should consider the implementation of FDCs as part of the broader WHO HEARTS [32] technical package. 
Other components of the strategy should consider how to decentralise and task-share care through sim-
plified treatment and monitoring algorithms such as those utilised in the treatment and management of 
HIV/AIDS. The rapid expansion of digital technologies, including the development of electronic decision 
support tools, should be harnessed to support FDC implementation. Use of such technology can facilitate 
prompt, time-efficient implementation of simplified FDC treatment algorithms and support community-
driven diagnosis and management. Development of clinical guidelines on the use of FDCs, endorsed by 
national opinion leaders, Ministries of Health, and CVD organisations, could also play an important role in 
integrating these formulations into national public health-based programmes. Importantly, any implemen-
tation strategies must be designed with a pragmatic approach, evaluated in real-world settings, and refined 
accordingly. A follow-up meeting of this symposium, including WHO and other key stakeholders, including 
researchers and funders, is planned to take concrete steps towards developing a global strategy supporting 
the implementation of FDCs for CVD.
Summary
Achieving the WHO 25 by 25 targets of at least 50% of eligible people receiving drug therapy and counsel-
ling to prevent heart attack and stroke and achieving 80% availability of essential medicines requires novel 
approaches. Use of single medicines from various drug classes, rather than combinations of such medicines, 
to address the risk associated with established CVD thus far has failed to provide a scalable, global solution 
to address the growing epidemic of CVD. FDC therapy in patients at high risk of CVD events has been shown 
to be effective in improving adherence and coverage of essential preventive medications and could be a core 
component to achieve WHO goals if part of global CVD prevention and control strategy.
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